New progress in innovative research and development of antitumor drugs in China

[China Pharmaceutical network industry trends] recently, Hengrui Medicine released a notice that the company and its subsidiary Shanghai Hengrui Medicine Co., Ltd will carry out the phase III clinical trial of shr-1316 injection in the near future It is reported that shr-1316 injection is a humanized anti-PD-L1 monoclonal antibody independently developed by the company, which is mainly used for the treatment of malignant tumors The R & D cost of the product project is about 60.18 million yuan It is understood that with the intensification of environmental pollution and the increasing pressure of life, the incidence rate of cancer in the world is increasing The demand for tumor diagnosis and treatment drugs is very strong The market space of anticancer drugs is very impressive in the next 10 years In recent years, China has also increased the research and development of anti-tumor drugs, and with the introduction of favorable policies, the development of anti-tumor drugs in China has also made some achievements "Since 2015, the heavy weight policy of medicine has been launched continuously, and the medical reform has entered a new historical height, which brings opportunities for the development of biopharmaceutics." Some industry figures said According to the 2017 China cancer registration annual report, China has 4.29 million new cancer cases every year, accounting for 20% of the global new cases The huge market space attracts many foreign pharmaceutical enterprises to march into China's anticancer drug market Facing foreign pharmaceutical giants, it has become a major issue for domestic pharmaceutical enterprises to produce high-quality and low-cost domestic drugs for the people, break the monopoly of international giants and replace imported drugs Now in the context of reform, the potential energy of innovation has been accumulated, the number of domestic innovative drugs has increased, and the innovation achievements have emerged However, as of December 2017, CFDA has approved 160 anti-tumor drugs (excluding auxiliary drugs), including 120 chemical drugs and 40 biological products; only 37 targeted drugs, 8 of which are domestic targeted drugs Only one third of the more than 90 targeted drugs approved by the FDA are on the market in China, and there are still few new anti-tumor drugs available for cancer patients in China Strengthening the innovation and research of anti-tumor drugs is still in the offing Some industry insiders said that 15 years ago, Chinese patients faced many difficulties, and independent research and development of new drugs is imperative The person said that under the high attention of the state, even though there are many difficulties, the talent plan, special plan for major new drug development and forward-looking infrastructure construction have achieved good results At the same time, a large number of returnees returned to China to start businesses, and biomedical enterprises were born After 2010, the capital market gradually recovered, China's biomedical investment grew strongly, and research projects also grew rapidly The author has learned that on the road of anti-tumor drug development, many pharmaceutical enterprises in China have begun to make continuous efforts to increase R & D investment In terms of policy, while actively shortening the approval time of new drugs and imported drugs, the state also implemented zero tariff on 28 drugs, including anti-cancer drugs, and promoted the inclusion of anti-tumor drugs in the medical insurance catalogue With the huge market demand and favorable policies, major enterprises are actively laying out their own cancer drug pipeline According to the data, there are 88 anti-cancer concept stocks, including Hengrui pharmaceutical, Fosun Pharmaceutical, Beida pharmaceutical, Kelun pharmaceutical, Shiyao group, Shanghai pharmaceutical, etc However, at present, there are still big problems in the innovative research and development of anti-tumor drugs, such as clinical trials For the innovative clinical trials of anti-tumor drugs, some experts pointed out that there are several ways to bring forth new ideas in the classics: first, to establish a scientific and reasonable minor repair; second, to make a reasonable breakthrough in the traditional concept; third, to make a seamless test - to change the skin and change the skin; fourth, to integrate the new concept into a basket and umbrella test; fifth, to study the real world He said that this is an era of brain burning, innovation and rapid development